The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Low-dose anti-PD-(L)1 inhibitor strategies: A systematic review.
 
Pablo Jiménez Labaig
Speakers' Bureau - MSD Oncology
Research Funding - Merck; Roche
Travel, Accommodations, Expenses - Merck; MSD; Novartis
 
Failah Mohamed Lamin
Travel, Accommodations, Expenses - MSD; Novartis
 
Nur Jihan Irwan Tan
No Relationships to Disclose
 
Ilves Sanna
No Relationships to Disclose
 
Khalid El Bairi
Leadership - NCODA
Honoraria - NCODA
Expert Testimony - techspert.io
 
Shah Zeb Khan
No Relationships to Disclose
 
Dario Trapani
No Relationships to Disclose
 
Teresa Amaral
Consulting or Advisory Role - CeCaVa; Delcath Systems; Medscape; Menarini; NeraCare GmbH; Novartis; Philogen; Pierre Fabre
Research Funding - Agenus (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Biotech IOB (Inst); BMS GmbH & Co. KG (Inst); HUYA Bioscience International (Inst); Immunocore (Inst); MSD (Inst); NeraCare GmbH (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Regeneron (Inst); Replimune (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst); Skyline Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - 18/384,708 ErbB-MEL ("EGFR")
Travel, Accommodations, Expenses - NeraCare GmbH
 
Amol Akhade
No Relationships to Disclose
 
Amol Patel
No Relationships to Disclose
 
Kevin Harrington
Honoraria - Abbvie (Inst); ALX Oncology (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Flamingo Pharma (Inst); GlaxoSmithKline (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); Merus (Inst); MSD (Inst); Nanobiotix (Inst); PDS Biotechnology (Inst); PsiVac Ltd (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)